WO2016021621A1 - 新規抗ヒトIgβ抗体 - Google Patents
新規抗ヒトIgβ抗体 Download PDFInfo
- Publication number
- WO2016021621A1 WO2016021621A1 PCT/JP2015/072162 JP2015072162W WO2016021621A1 WO 2016021621 A1 WO2016021621 A1 WO 2016021621A1 JP 2015072162 W JP2015072162 W JP 2015072162W WO 2016021621 A1 WO2016021621 A1 WO 2016021621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- human
- heavy chain
- human igβ
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to an anti-human Ig ⁇ antibody useful as an active ingredient of a pharmaceutical composition.
- the B cell receptor is composed of a membrane-bound immunoglobulin molecule (mIg) associated with a heterodimer of Ig ⁇ (CD79A) and Ig ⁇ (CD79B).
- the antigen binds to mIg and aggregates the receptor, and the Ig ⁇ / Ig ⁇ subunit transmits a signal into B cells (Mol. Immunol., Vol. 41, p. 599-613, 2004).
- the Fc ⁇ receptor (Fc ⁇ R) protein family which is an Fc receptor for IgG antibodies, has immunosuppressive functions, including Fc ⁇ RIa (CD64A), Fc ⁇ RIIa (CD32A), and Fc ⁇ RIIIa (CD16A), which have immunoactive functions. Having Fc ⁇ RIIb (CD32B) has been reported. It has been reported that when BCR and Fc ⁇ RIIb on B cells are cross-linked via IgG immune complex, B cell activation is suppressed, and B cell proliferation and antibody production are suppressed (Nat. Rev. Immunol., Vol. 10, p.328-343, 2010, Nat.Rev. Immunol., Vol.8, p.34-47, 2008, Nat.Rev. Immunol., Vol.2, p.580. -592, 2002).
- suppression of antibody production by controlling B cell activation via Fc ⁇ RIIb is effective in the treatment of autoimmune diseases in which autoantibodies are associated with pathological conditions.
- Idiopathic thrombocytopenic purpura is an autoimmune disease in which platelet destruction occurs due to autoantibodies against autologous platelets (Autoimmun. Rev., Vol. 13, p. 577-583, 2014). In animals given anti-platelet antibodies, thrombocytopenia is induced (Br. J. Haematol., Vol. 167, p. 110-120, 2014), and reducing autoantibodies can cause idiopathic thrombocytopenic purpura. It has been reported that it is effective for treatment (Ther. Apher. Dial. Vol. 16, p. 311-320, 2012, Lupus, Vol. 22, p. 664-674, 2013).
- a monoclonal antibody that crosslinks BCR and Fc ⁇ RIIb and enhances the immunosuppressive function of Fc ⁇ RIIb can be developed, it can be used for prevention and treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and idiopathic thrombocytopenic purpura. Expected to be useful.
- Examples of antibodies that cross-link BCR and Fc ⁇ RIIb include DART (patent document 1, non-patent document 1), which is a bispecific antibody against Ig ⁇ and Fc ⁇ RIIb, and a variable region that binds to CD19 that is part of the BCR complex and Fc ⁇ RIIb.
- DART pattern 1, non-patent document 1
- Anti-CD19 S267E / L328F Patent Document 2, Non-Patent Documents 2 and 3 having an Fc region with enhanced affinity for NP has been reported.
- An object of the present invention is to provide an anti-human Ig ⁇ antibody that crosslinks BCR and Fc ⁇ RIIb and has an enhanced immunosuppressive function compared to conventional antibodies.
- CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2 and amino acid numbers 50 to 65 of SEQ ID NO: 2.
- CDR2 consisting of amino acid sequence
- heavy chain variable region comprising CDR3 consisting of amino acid sequence from amino acid number 98 to 108 of SEQ ID NO: 2
- CDR1 consisting of amino acid sequence from amino acid number 24 to 38 of SEQ ID NO: 4
- SEQ ID NO: A light chain variable region comprising CDR2 consisting of amino acid sequence 54 of amino acids 4 to 60 and CDR3 consisting of amino acid sequence 93 to 101 of SEQ ID NO: 4, wherein the heavy chain constant region of the antibody is S239D , H268D, and L328W human Ig ⁇ 1 constant regions with amino acid mutations
- a plurality of anti-human Ig ⁇ antibodies (Examples 1 to 3), which bind to human Ig ⁇ on human B cells (Examples 4 and 5) and induce anti-IgM antibody-induced human B It was found to inhibit cell activation (Example 6).
- the anti-human Ig ⁇ antibody was provided and the present invention was completed. Furthermore, the antibody suppresses plasma human antibody titer in a human PBMC-introduced NOG mouse model (Example 7), and affects the total antibody titer in plasma in a monkey TTx antigen sensitization model. It was found that the antigen-specific antibody was suppressed (Example 8).
- this invention includes the following invention as a medically or industrially useful substance or method.
- An anti-human Ig ⁇ antibody CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 65 of SEQ ID NO: 2, and SEQ ID NO: 2
- Heavy chain variable region comprising CDR3 consisting of amino acid sequence from amino acid number 98 to 108, CDR1 consisting of amino acid sequence from amino acid number 24 to 38 of SEQ ID NO: 4, amino acid sequence from amino acid number 54 to 60 of SEQ ID NO: 4
- a heavy chain constant that is a human Ig ⁇ 1 constant region having amino acid mutations of S239D, H268D, and L328W, comprising a light chain variable region comprising CDR2 comprising SEQ ID NO: 4 and CDR3 comprising amino acid sequences 93 to 101 of SEQ ID NO: 4
- An anti-human Ig ⁇ antibody comprising a region.
- the anti-human Ig ⁇ antibody according to (1) which is a humanized antibody.
- a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 4 to amino acid numbers 1 to 112, S239D, H268D, And a heavy chain constant region which is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W, and the anti-human Ig ⁇ antibody according to (3).
- (6) comprising a heavy chain variable region comprising the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 12, S239D, H268D, And a heavy chain constant region which is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W, and the anti-human Ig ⁇ antibody according to (3).
- An anti-human Ig ⁇ antibody produced by post-translational modification of the anti-human Ig ⁇ antibody according to any one of (4) to (6).
- the anti-human Ig ⁇ antibody according to (1) comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4.
- the anti-human Ig ⁇ antibody according to (1) comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 10 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 12.
- a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (1) to (6).
- a polynucleotide comprising a base sequence encoding the light chain of the anti-human Ig ⁇ antibody according to any one of (1) to (6).
- An expression vector comprising the polynucleotide according to (18) and / or (19).
- a method for producing an anti-human Ig ⁇ antibody comprising culturing a host cell selected from the group consisting of the following (a) to (c) and expressing the anti-human Ig ⁇ antibody: (A) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (1) to (6) and a polynucleotide comprising a base sequence encoding the light chain of the antibody; (A host cell transformed with an expression vector comprising: (B) an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (1) to (6) and a base sequence encoding the light chain of the antibody; A host cell transformed with an expression vector comprising the polynucleotide comprising; and (c) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (1)
- a method for producing an anti-human Ig ⁇ antibody comprising culturing a host cell selected from the group consisting of the following (a) to (c) and expressing the anti-human Ig ⁇ antibody: (A) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (10) to (13), and a polynucleotide comprising a base sequence encoding the light chain of the antibody; A host cell transformed with an expression vector comprising: (B) an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any one of (10) to (13) and a base sequence encoding the light chain of the antibody; A host cell transformed with an expression vector comprising the polynucleotide comprising; and (c) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody according to any
- autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura.
- Preventing or treating an autoimmune disease comprising a step of administering a therapeutically effective amount of the anti-human Ig ⁇ antibody according to any one of (1) to (17), (25) and (26) Method.
- the anti-human Ig ⁇ antibody of the present invention has an excellent immunosuppressive action by inhibiting B cell activation, and is an autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura It can be used as a preventive or therapeutic agent.
- Figure 2 shows the inhibitory effect of humanized anti-Ig ⁇ antibody on anti-IgM antibody-induced cell proliferation in human B cells.
- the vertical axis represents the proliferation rate of B cells, and the horizontal axis represents the added antibody concentration ( ⁇ g / mL).
- the inhibitory effect of a humanized anti-Ig ⁇ antibody on the increase in human IgM antibody titer in plasma caused by transferring human PBMC into NOG mice is shown.
- the vertical axis represents the human IgM antibody titer in plasma ( ⁇ g / mL), and the horizontal axis represents the time (days) since human PBMC was transferred to NOG mice.
- the inhibitory effect of a humanized anti-Ig ⁇ antibody on the increase in human IgE antibody titer in plasma caused by transferring human PBMC into NOG mice is shown.
- the vertical axis represents the plasma human IgE antibody titer (ng / mL), and the horizontal axis represents the time (day) since human PBMC was transferred to NOG mice.
- FIG. 6 shows the inhibitory effect of a humanized anti-Ig ⁇ antibody on the increase of anti-precipitating tetanus toxoid antibody titer in plasma caused by immunizing monkeys with precipitated tetanus toxoid.
- the vertical axis represents the plasma anti-precipitation tetanus toxoid antibody titer (U / mL), and the horizontal axis represents the time (day) after immunization of the monkey with precipitated tetanus toxoid.
- FIG. 5 shows the effect of humanized anti-Ig ⁇ antibody on plasma total IgM antibody titer in monkeys immunized with precipitated tetanus toxoid.
- the vertical axis represents plasma total IgM antibody titer (U / mL), and the horizontal axis represents time (days) after immunization of monkeys with precipitated tetanus toxoid.
- Figure 6 shows the effect of humanized anti-Ig ⁇ antibodies on plasma total IgA antibody titers in monkeys immunized with precipitated tetanus toxoid.
- the vertical axis represents plasma total IgA antibody titer (U / mL), and the horizontal axis represents time (days) after immunization of monkeys with precipitated tetanus toxoid.
- Figure 6 shows the effect of humanized anti-Ig ⁇ antibodies on plasma total IgG antibody titers in monkeys immunized with precipitated tetanus toxoid.
- the vertical axis represents plasma total IgG antibody titer (U / mL), and the horizontal axis represents time (days) after immunization of monkeys with precipitated tetanus toxoid.
- IgG There are five classes of antibodies: IgG, IgM, IgA, IgD, and IgE.
- the basic structure of an antibody molecule is common to each class, and is composed of a heavy chain having a molecular weight of 50,000 to 70,000 and a light chain having a molecular weight of 20,000 to 30,000.
- the heavy chain is usually composed of a polypeptide chain containing about 440 amino acids, has a characteristic structure for each class, and corresponds to IgG, IgM, IgA, IgD, IgE, Ig ⁇ , Ig ⁇ , Ig ⁇ , Ig ⁇ . It is called.
- IgG has IgG1, IgG2, IgG3, and IgG4 subclasses, and the corresponding heavy chains are called Ig ⁇ 1, Ig ⁇ 2, Ig ⁇ 3, and Ig ⁇ 4.
- the light chain is usually composed of a polypeptide chain containing about 220 amino acids, and two types of L-type and K-type are known, and are called Ig ⁇ and Ig ⁇ , respectively.
- the peptide structure of the basic structure of an antibody molecule has a molecular weight of 150,000 to 190,000, in which two heavy chains and two light chains that are homologous are linked by a disulfide bond (SS bond) and a non-covalent bond, respectively. .
- the two light chains can be paired with any heavy chain.
- Each antibody molecule always consists of two identical light chains and two identical heavy chains.
- a domain located at the amino terminus (N terminus) of both heavy and light chains is called a variable region because its amino acid sequence is not constant even if it is a specimen from the same class (subclass) of the same species.
- Each domain is called a heavy chain variable region and a light chain variable region.
- the amino acid sequence on the carboxy terminus (C terminus) side of the variable region is almost constant for each class or subclass and is called a constant region.
- the antigen-binding site of an antibody is composed of a heavy chain variable region and a light chain variable region, and the specificity of binding depends on the amino acid sequence of this site.
- biological activities such as binding to complement and various cells reflect differences in the structure of the constant region of each class Ig. It has been found that the variability of the light chain and heavy chain variable regions is almost limited to the three small hypervariable regions present in both chains, these regions being complementarity determining regions (CDRs; each N-terminal). From the side, they are called CDR1, CDR2, CDR3).
- CDR1, CDR2, CDR3 complementarity determining regions
- the remaining part of the variable region is called the framework region (FR) and is relatively constant.
- the anti-human Ig ⁇ antibody of the present invention includes an anti-human Ig ⁇ antibody having the following characteristics.
- a light chain variable region comprising CDR3 consisting of the amino acid sequence from amino acid number 93 to 101 of SEQ ID NO: 4, and a heavy chain constant region that is a human Ig ⁇ 1 constant region having amino acid mutations of S239D, H268D, and L328W Anti-
- the anti-human Ig ⁇ antibody of the present invention is a humanized antibody.
- “humanized antibody” means an antibody in a form that includes a CDR derived from a murine antibody and other antibody portions derived from a human antibody. Methods for producing humanized antibodies are known in the art, and can be produced with reference to, for example, US Pat. Nos. 5,225,539 and 6,180,370.
- the anti-human Ig ⁇ antibody of the present invention is the anti-human Ig ⁇ antibody described in any of the following 1) to 3): 1) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 2 from amino acid numbers 1 to 119, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 4 from amino acid numbers 1 to 112, S239D, H268D, and An anti-human Ig ⁇ antibody comprising a heavy chain constant region that is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W; 2) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 6 from amino acid numbers 1 to 119, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 8 from amino acid numbers 1 to 112, S239D, H268D, and An anti-human Ig ⁇ antibody comprising a heavy chain constant region which is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W; and 3) a heavy chain variable
- the EU index (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Public Health, of Health, Bethesda).
- S239D is a substitution of serine at amino acid position 239 with aspartic acid according to the EU index of Kabat et al.
- H268D is a substitution of histidine at position 268 with aspartic acid according to the EU index of Kabat et al. In the human Ig ⁇ 1 constant region.
- L328W is substitution of leucine at amino acid position 328 with tryptophan according to the EU index of Kabat et al.
- human Ig ⁇ 1 constant region examples of the human Ig ⁇ 1 constant region having amino acid mutations of S239D, H268D, and L328W include a human Ig ⁇ 1 constant region consisting of the amino acid sequence of SEQ ID NO: 2 from amino acid number 120 to 449.
- the light chain constant region of the anti-human Ig ⁇ antibody of the present invention either Ig ⁇ or Ig ⁇ constant region can be selected, but the human Ig ⁇ constant region is preferred.
- the human Ig ⁇ constant region include a human Ig ⁇ constant region consisting of the amino acid sequence from amino acid numbers 113 to 218 of SEQ ID NO: 4.
- the anti-human Ig ⁇ antibody of the present invention is an anti-human Ig ⁇ antibody selected from any of the following i) to iii): i) an anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4; ii) an anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 6 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 8; and iii) a heavy consisting of the amino acid sequence shown in SEQ ID NO: 10
- the anti-human Ig ⁇ antibody of the present invention includes an anti-human Ig ⁇ antibody subjected to post-translational modification.
- anti-human Ig ⁇ antibodies of the invention that have undergone post-translational modification include anti-human Ig ⁇ antibodies that have undergone pyroglutamylation at the heavy chain variable region N-terminus and / or lysine deletion at the heavy chain C-terminus. It is known in the art that such post-translational modification by N-terminal pyroglutamylation or C-terminal lysine deletion does not affect the activity of the antibody (Analytical Biochemistry, Vol. 348, p. 24). -39, 2006).
- the anti-human Ig ⁇ antibody of the present invention includes the anti-human Ig ⁇ antibodies described in the following 1) to 3): 1) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2 in which glutamic acid of amino acid number 1 is modified to pyroglutamic acid and / or lacking lysine of amino acid number 449, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4; Anti-human Ig ⁇ antibody.
- the anti-human Ig ⁇ antibody of the present invention is an anti-human Ig ⁇ antibody selected from any of the following i) to iii): i) An anti-human Ig ⁇ antibody comprising a heavy chain comprising the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 2 and a light chain comprising the amino acid sequence represented by SEQ ID NO: 4.
- an anti-human comprising a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 6 in which glutamine of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 8
- An anti-human Ig ⁇ antibody comprising an Ig ⁇ antibody
- a person skilled in the art can produce a fusion product of an antibody and another peptide or protein, or can produce a modified product to which a modifying agent is bound, based on the present invention.
- Antibodies are also included in the antibodies of the present invention.
- Other peptides and proteins used for the fusion are not particularly limited as long as they do not reduce the binding activity of the antibody.
- human serum albumin, various tag peptides, artificial helix motif peptide, maltose binding protein, glutathione S transferase Examples include various toxins and other peptides or proteins that can promote multimerization.
- the modifying agent used for modification is not particularly limited as long as it does not reduce the binding activity of the antibody, and examples thereof include polyethylene glycol, sugar chain, phospholipid, liposome, and low molecular weight compound.
- anti-human Ig ⁇ antibody means an antibody that binds to human Ig ⁇ . Whether or not it binds to human Ig ⁇ can be confirmed using a known binding activity measurement method. Examples of the method for measuring the binding activity include a method such as Enzyme-Linked ImmunoSorbent Assay (ELISA).
- ELISA Enzyme-Linked ImmunoSorbent Assay
- human Ig ⁇ -Flag protein for example, encoded by the nucleotide sequence of SEQ ID NO: 13
- a test antibody is added thereto for reaction
- a secondary antibody such as an anti-IgG antibody labeled with an enzyme such as horseradish peroxidase (HRP) is reacted.
- HRP horseradish peroxidase
- the binding of the secondary antibody is identified by measuring the activity using a reagent that detects the activity (for example, in the case of HRP labeling, BM-Chemiluminescence ELISA Substrate (POD) (Roche Diagnostics))
- a reagent that detects the activity for example, in the case of HRP labeling, BM-Chemiluminescence ELISA Substrate (POD) (Roche Diagnostics)
- the anti-human Ig ⁇ antibody of the present invention includes an antibody that binds to human Ig ⁇ as well as Ig ⁇ derived from other animals (eg, monkey Ig ⁇ ) as long as it binds to human Ig ⁇ .
- the binding activity to human B cells and the activity of inhibiting the activation of human B cells by BCR stimulation may be evaluated.
- an activity evaluation method a method as described in Examples 5 and 6 below can be used.
- the anti-human Ig ⁇ antibody of the present invention has an activity of binding to human Ig ⁇ and inhibiting the activation of human B cells by BCR stimulation.
- the anti-human Ig ⁇ antibodies of the present invention can be easily obtained by those skilled in the art using methods known in the art based on the heavy chain and light chain sequence information of the antibodies of the present invention disclosed herein. Can be made.
- the anti-human Ig ⁇ antibody of the present invention is not particularly limited. For example, the method described in ⁇ Method for producing anti-human Ig ⁇ antibody of the present invention and anti-human Ig ⁇ antibody produced by the method> described later> Can be manufactured according to
- the anti-human Ig ⁇ antibody of the present invention is further purified if necessary, and then formulated according to a conventional method.
- autoimmune diseases such as autoimmune hemolytic anemia, pemphigus, antiphospholipid antibody syndrome, ANCA-related vasculitis, Sjogren's syndrome, Hashimoto's disease, chronic inflammatory demyelinating polyneuritis and chronic fatigue syndrome
- autoimmune diseases such as autoimmune hemolytic anemia, pemphigus, antiphospholipid antibody syndrome, ANCA-related vasculitis, Sjogren's syndrome, Hashimoto's disease, chronic inflammatory demyelinating polyneuritis and chronic fatigue syndrome.
- the polynucleotide of the present invention includes a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising a base sequence encoding the light chain of the anti-human Ig ⁇ antibody of the present invention. included.
- the polynucleotide comprising the base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention is a polynucleotide comprising the base sequence encoding the heavy chain consisting of the amino acid sequence represented by SEQ ID NO: 2, sequence A polynucleotide containing a base sequence encoding a heavy chain consisting of the amino acid sequence shown in No. 6 or a polynucleotide containing a base sequence encoding a heavy chain consisting of the amino acid sequence shown in SEQ ID No. 10.
- Examples of the polynucleotide containing a base sequence encoding a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 2 include a polynucleotide containing the base sequence shown in SEQ ID NO: 1 or 15.
- a polynucleotide containing the base sequence which codes the heavy chain which consists of an amino acid sequence shown by sequence number 6 the polynucleotide containing the base sequence shown by sequence number 5 is mentioned, for example.
- As a polynucleotide containing the base sequence which codes the heavy chain which consists of an amino acid sequence shown by sequence number 10 the polynucleotide containing the base sequence shown by sequence number 9 is mentioned, for example.
- the polynucleotide comprising the base sequence encoding the light chain of the anti-human Ig ⁇ antibody of the present invention is a polynucleotide comprising the base sequence encoding the light chain consisting of the amino acid sequence shown in SEQ ID NO: 4, sequence A polynucleotide containing a base sequence encoding a light chain consisting of the amino acid sequence shown in No. 8, or a polynucleotide containing a base sequence encoding a light chain consisting of the amino acid sequence shown in SEQ ID No. 12.
- Examples of the polynucleotide containing the base sequence encoding the light chain consisting of the amino acid sequence shown in SEQ ID NO: 4 include the polynucleotide containing the base sequence shown in SEQ ID NO: 3.
- the polynucleotide containing the base sequence which codes the light chain which consists of an amino acid sequence shown by sequence number 8 the polynucleotide containing the base sequence shown by sequence number 7 is mentioned, for example.
- As a polynucleotide containing the base sequence which codes the light chain which consists of an amino acid sequence shown by sequence number 12 the polynucleotide containing the base sequence shown by sequence number 11 is mentioned, for example.
- the polynucleotide of the present invention can be easily prepared by those skilled in the art using a method known in the art based on the base sequence.
- the polynucleotide of the present invention can be synthesized using gene synthesis methods known in the art.
- gene synthesis method various methods known to those skilled in the art, such as an antibody gene synthesis method described in WO90 / 07861, can be used.
- the expression vector of the present invention includes an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention, and a polynucleotide comprising a base sequence encoding the light chain of the anti-human Ig ⁇ antibody of the present invention.
- An expression vector comprising a nucleotide, and an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising a base sequence encoding the light chain of the antibody are included.
- Expression vectors used for expressing the polynucleotide of the present invention include various host cells such as eukaryotic cells (eg, animal cells, insect cells, plant cells, yeast) and / or prokaryotic cells (eg, E. coli).
- eukaryotic cells eg, animal cells, insect cells, plant cells, yeast
- prokaryotic cells eg, E. coli
- a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and / or a polynucleotide comprising a base sequence encoding the light chain of the anti-human Ig ⁇ antibody of the present invention is expressed and encoded by these There is no particular limitation as long as the polypeptide can be produced.
- expression vectors examples include plasmid vectors, virus vectors (eg, adenoviruses, retroviruses) and the like.
- virus vectors eg, adenoviruses, retroviruses
- pEE6.4 or pEE12.4 can be used. .
- the expression vector of the present invention may contain a promoter operably linked to the polynucleotide of the present invention.
- promoters for expressing the polynucleotide of the present invention in animal cells include virus-derived promoters such as CMV, RSV, SV40, actin promoter, EF (longation factor) 1 ⁇ promoter, heat shock promoter, and the like.
- examples of the promoter for expressing the polynucleotide of the present invention in bacteria include trp promoter, lac promoter, ⁇ PL promoter, tac promoter and the like.
- the promoter for expressing the polynucleotide of the present invention in yeast include GAL1 promoter, GAL10 promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter and the like.
- the expression vector of the present invention may contain a start codon and a stop codon.
- the enhancer sequence, the 5 ′ and 3 ′ untranslated regions of the gene encoding the antibody of the present invention or its heavy chain or light chain, secretory signal sequence, splicing junction, polyadenylation site, or replicable Units may be included.
- the expression vector of the present invention may contain a start codon, a stop codon, a terminator region, and a replicable unit.
- the expression vector of the present invention may contain a selection marker (for example, tetracycline resistance gene, ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, dihydrofolate reductase gene) that is usually used depending on the purpose.
- a selection marker for example, tetracycline resistance gene, ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, dihydrofolate reductase gene
- the transformed host cell of the present invention includes a host cell transformed with the expression vector of the present invention selected from the group consisting of the following (a) to (d).
- A a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising a base sequence encoding the light chain of the antibody;
- B transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and an expression vector comprising a polynucleotide comprising the base sequence encoding the light chain of the antibody Host cell;
- C a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention; and (d)
- Preferred transformed host cells of the present invention include a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising a base sequence encoding the light chain of the antibody.
- a host cell transformed with an expression vector, and an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising the base sequence encoding the light chain of the antibody And a host cell transformed with an expression vector.
- the host cell to be transformed is not particularly limited as long as it is compatible with the expression vector to be used and can be transformed with the expression vector to express the antibody.
- Examples of host cells to be transformed include various cells (for example, animal cells (for example, CHOK1SV cells), insect cells (for example, natural cells or artificially established cells) commonly used in the technical field of the present invention. Sf9), bacteria (such as Escherichia), yeast (such as Saccharomyces and Pichia)), and preferably, cultured cells such as CHOK1SV cells, CHO-DG44 cells, 293 cells, and NS0 cells are used. be able to.
- the method for transforming the host cell is not particularly limited, and for example, a calcium phosphate method, an electroporation method, or the like can be used.
- the method for producing an anti-human Ig ⁇ antibody of the present invention includes a step of culturing a host cell selected from the group consisting of the following (a) to (c) and expressing the anti-human Ig ⁇ antibody: Methods for producing Ig ⁇ antibodies are included.
- A a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and a polynucleotide comprising a base sequence encoding the light chain of the antibody;
- B transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human Ig ⁇ antibody of the present invention and an expression vector comprising a polynucleotide comprising the base sequence encoding the light chain of the antibody A host cell; and
- the method for producing the anti-human Ig ⁇ antibody of the present invention is not particularly limited as long as it includes the step of culturing the transformed host cell of the present invention and expressing the anti-human Ig ⁇ antibody.
- Preferred host cells used in the method include the above-described preferred transformed host cells of the present invention.
- the cultured host cells can be cultured by a known method.
- the culture conditions such as temperature, pH of the medium and culture time are appropriately selected.
- the medium include MEM medium (Science, Vol. 130, p. 432-437, 1959) containing about 5 to 20% fetal bovine serum, DMEM medium (Virology, Vol. 8, p.396, 1959), RPMI 1640 medium (J. Am. Med. Assoc., Vol. 199, p. 519, 1967), 199 medium (Exp. Biol. Med., Vol. 73, p. 1- 8, 1950) or the like.
- the pH of the medium is preferably about 6 to 8, and the culture is usually carried out at about 30 to 40 ° C.
- the host cell is an insect cell, for example, Grace's medium containing fetal bovine serum (Proc. Natl. Acad. Sci. USA, Vol. 82, p. 8404, 1985) can be used as the medium. .
- the pH of the medium is preferably about 5 to 8, and the culture is usually carried out at about 20 to 40 ° C. for about 15 to 100 hours with aeration and agitation as necessary.
- a liquid medium containing a nutrient source is appropriate.
- the nutrient medium preferably contains a carbon source, an inorganic nitrogen source, or an organic nitrogen source necessary for the growth of transformed host cells.
- the carbon source include glucose, dextran, soluble starch, and sucrose.
- the inorganic nitrogen source or organic nitrogen source include ammonium salts, nitrates, amino acids, corn steep liquor, peptone, casein, and meat extract. , Soybean meal, potato extract and the like.
- other nutrients eg, inorganic salts (eg, calcium chloride, sodium dihydrogen phosphate, magnesium chloride), vitamins
- antibiotics eg, tetracycline, neomycin, ampicillin, kanamycin
- the pH of the medium is preferably about 5-8.
- preferred media include LB medium, M9 medium (Mol. Clo., Cold Spring Harbor Laboratory, Vol. 3, A2.2) and the like. Cultivation is usually carried out at about 14 to 43 ° C. for about 3 to 24 hours with aeration or agitation as necessary.
- yeast for example, a Burkholder minimum medium (Proc. Natl. Acad. Sci. USA, Vol. 77, p. 4505, 1980) can be used. Cultivation is usually carried out at about 20 to 35 ° C. for about 14 to 144 hours with aeration and agitation, if necessary.
- the anti-human Ig ⁇ antibody of the present invention can be expressed.
- the method for producing the anti-human Ig ⁇ antibody of the present invention includes the step of culturing the transformed host cell of the present invention and expressing the anti-human Ig ⁇ antibody, and further, anti-human Ig ⁇ antibody from the transformed host cell.
- a step of recovering, preferably isolating or purifying human Ig ⁇ antibody may be included.
- Isolation or purification methods include, for example, methods using solubility such as salting out and solvent precipitation, methods using differences in molecular weight such as dialysis, ultrafiltration and gel filtration, ion exchange chromatography and hydroxylapatite chromatography.
- the antibody accumulated in the culture supernatant can be purified by various chromatography, for example, column chromatography using a protein A column or a protein G column.
- the anti-human Ig ⁇ antibody of the present invention includes an anti-human Ig ⁇ antibody produced by the method for producing the anti-human Ig ⁇ antibody of the present invention.
- the pharmaceutical composition of the present invention includes a pharmaceutical composition comprising the anti-human Ig ⁇ antibody of the present invention and a pharmaceutically acceptable excipient.
- the pharmaceutical composition of the present invention can be prepared by an ordinarily used method using an excipient usually used in the art, that is, a pharmaceutical excipient or a pharmaceutical carrier.
- Examples of dosage forms of these pharmaceutical compositions include parenteral agents such as injections and infusions, and can be administered by intravenous administration, subcutaneous administration, or the like.
- parenteral agents such as injections and infusions, and can be administered by intravenous administration, subcutaneous administration, or the like.
- excipients, carriers, additives and the like corresponding to these dosage forms can be used within a pharmaceutically acceptable range.
- the pharmaceutical composition of the present invention may contain a plurality of types of anti-human Ig ⁇ antibodies of the present invention.
- the present invention includes a pharmaceutical composition containing an antibody that has not undergone post-translational modification and an antibody produced by post-translational modification.
- the pharmaceutical composition of the present invention comprises an anti-human Ig ⁇ antibody selected from the group consisting of the following (1) to (3), and an anti-translational modification caused by post-translational modification of the anti-human Ig ⁇ antibody.
- an anti-human Ig ⁇ antibody selected from the group consisting of the following (1) to (3), and an anti-translational modification caused by post-translational modification of the anti-human Ig ⁇ antibody.
- (1) comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 6 from amino acid numbers 1 to 119 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 8 from amino acid numbers 1 to 112, S239D, H268D, And an anti-human Ig ⁇ antibody comprising a heavy chain constant region that is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W; (2) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 2 from amino acid numbers 1 to 119, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 4 from amino acid numbers 1 to 112, S239D, H268D, And an anti-human Ig ⁇ antibody comprising a heavy chain constant region that is a human Ig ⁇ 1 constant region having an amino acid mutation of L328W; and (3) a heavy chain variable region comprising the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 10, and An anti-human Ig ⁇ antibody compris
- the pharmaceutical composition of the present invention includes a heavy chain C-terminal lysine-deleted antibody, an antibody that has undergone N-terminal post-translational modification, an antibody that has lost the heavy chain C-terminal lysine and has undergone N-terminal post-translational modification, and / or Alternatively, a pharmaceutical composition containing an antibody having a heavy chain C-terminal lysine and not subjected to N-terminal posttranslational modification is also included.
- the pharmaceutical composition of the present invention containing an anti-human Ig ⁇ antibody also includes a pharmaceutical composition containing two or more anti-human Ig ⁇ antibodies among the following (1) to (4): .
- An anti-human Ig ⁇ antibody comprising a heavy chain comprising the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 2 and a light chain comprising the amino acid sequence represented by SEQ ID NO: 4.
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2 in which glutamic acid of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4.
- an anti-antibody comprising a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 2 in which glutamic acid of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence represented by SEQ ID NO: 4 Human Ig ⁇ antibody.
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 4.
- the pharmaceutical composition of the present invention containing an anti-human Ig ⁇ antibody also includes a pharmaceutical composition containing two or more anti-human Ig ⁇ antibodies among the following (1) to (4): .
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 6 and a light chain consisting of the amino acid sequence represented by SEQ ID NO: 8.
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 6 in which glutamine of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 8.
- the pharmaceutical composition of the present invention containing an anti-human Ig ⁇ antibody also includes a pharmaceutical composition containing two or more anti-human Ig ⁇ antibodies among the following (1) to (4): .
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 from amino acid number 1 to 448 and a light chain consisting of the amino acid sequence represented by SEQ ID NO: 12.
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10 in which glutamic acid of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 12.
- an anti-antibody comprising a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 448 of SEQ ID NO: 10 wherein glutamic acid of amino acid number 1 is modified with pyroglutamic acid, and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 12 Human Ig ⁇ antibody.
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 10 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 12.
- the pharmaceutical composition of the present invention is the pharmaceutical composition described below:
- An anti-human Ig ⁇ antibody comprising a heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 6 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 8, amino acid number of SEQ ID NO: 6 in which glutamine of amino acid number 1 is modified with pyroglutamic acid
- a pharmaceutical composition comprising an anti-human Ig ⁇ antibody comprising a heavy chain consisting of an amino acid sequence of 1 to 448 and a light chain consisting of the amino acid sequence shown in SEQ ID NO: 8, and a pharmaceutically acceptable excipient.
- the addition amount of the anti-human Ig ⁇ antibody of the present invention in the formulation varies depending on the degree and age of the patient's symptoms, the dosage form of the formulation used, the antibody binding titer, etc., for example, 0.001 mg / kg to 100 mg / Kg or so can be used.
- the pharmaceutical composition of the present invention comprises systemic lupus erythematosus, rheumatoid arthritis, idiopathic thrombocytopenic purpura, myasthenia gravis, Graves' disease, optic neuromyelitis, autoimmune hemolytic anemia, pemphigus, antiphospholipid antibody syndrome , ANCA-related vasculitis, Sjogren's syndrome, Hashimoto's disease, chronic inflammatory demyelinating polyneuritis, and chronic fatigue syndrome.
- the present invention includes a pharmaceutical composition for preventing or treating systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura comprising the anti-human Ig ⁇ antibody of the present invention.
- the present invention also includes a method for treating or preventing systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura, which comprises the step of administering a therapeutically effective amount of the anti-human Ig ⁇ antibody of the present invention.
- the present invention also includes the anti-human Ig ⁇ antibody of the present invention for use in the prevention or treatment of systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura.
- the present invention also includes the use of the anti-human Ig ⁇ antibody of the present invention in the manufacture of a pharmaceutical composition for the prevention or treatment of systemic lupus erythematosus, rheumatoid arthritis or idiopathic thrombocytopenic purpura.
- Example 1 Acquisition of human and monkey Ig ⁇ -Flag proteins
- a protein in which a Flag tag was bound to human Ig ⁇ human Ig ⁇ -Flag protein
- a protein in which a Flag tag was bound to monkey Ig ⁇ monkey Ig ⁇ (monkey Ig ⁇ -Flag protein) were obtained.
- the human Ig ⁇ -Flag gene (SEQ ID NO: 13) was recombined into the GS vector pEE6.4 (Lonza Biologics).
- the monkey Ig ⁇ -Flag gene (SEQ ID NO: 14) was recombined into the GS vector pEE6.4 (Lonza Biologicals).
- Each of the produced vectors was introduced into FreeStyle 293 cells (Life Technologies) using FreeStyle MAX Reagent (Life Technologies).
- Each cell was cultured in a serum-free culture system using FreeStyle 293 Expression medium (Life Technologies) for 1 week, and then a culture supernatant containing human Ig ⁇ -Flag protein or monkey Ig ⁇ -Flag protein was obtained.
- the protein was purified from the obtained culture supernatant using an anti-FLAG M2 antibody affinity gel (SIGMA-ALDRICH) and used for the following experiments.
- Example 2 Acquisition of anti-human Ig ⁇ antibody
- the human Ig ⁇ -Flag protein and monkey Ig ⁇ -Flag protein obtained in Example 1 were added to C3H / HeJJmsSlc-lpr / lpr mice (Japan SLC) together with an adjuvant that elicits an immune reaction. I was immunized. Mice were immunized several times for final immunization.
- the spleen and lymph nodes of the immunized mouse were removed, lymphocytes were collected, and this was cell-fused with mouse myeloma cells SP2 / 0 (ATCC CRL-1581) to prepare a hybridoma.
- a hybridoma limiting dilution sample was prepared and monocloned.
- the medium was changed to Hybridoma SFM (Life Technologies), which is a serum-free medium, and cultured for 3 to 5 days.
- the antibody was purified from the obtained culture supernatant using an antibody purification kit Protein G Purification kit (Proteus).
- the antibodies obtained from each clone were evaluated for binding activity to human and monkey Ig ⁇ -Flag proteins and binding activity to human and monkey B cells. As a result, it was found that an antibody designated CL6_40 binds to both human and monkey Ig ⁇ -Flag proteins and has high binding activity to both human and monkey B cells.
- CL6_40 genes encoding antibody heavy and light chains were cloned from the hybridoma and sequenced.
- Example 3 Production of humanized antibody
- the light chain and heavy chain CDRs of CL6_40 were grafted onto other human antibodies to generate multiple humanized antibody heavy and light chain genes.
- An expression vector containing both heavy chain and light chain genes of each humanized antibody was constructed using a GS vector (Lonza Biologics). Specifically, a gene encoding a signal sequence (N. White et al., Protein Eng., Vol. 1, p.
- the constant region gene of human Ig ⁇ 1 having the amino acid mutations of S239D, H268D, and L328W (consisting of the nucleotide sequence from base numbers 358 to 1350 of SEQ ID NO: 1) is connected to the 3 ′ side, and this heavy chain gene is connected to the GS vector Inserted into pEE6.4.
- a gene encoding a signal sequence (N. White et al., Supra) is located 5 ′ of the light chain variable region gene of each humanized antibody, and a human ⁇ chain constant region gene (sequence) is 3 ′.
- the light chain gene was inserted into the GS vector pEE12.4, each consisting of a base sequence from base numbers 337 to 657 of number 3).
- the heavy chain base sequence of the prepared humanized antibody CL6_40m12_DDW is represented by SEQ ID NO: 1 and SEQ ID NO: 15, the amino acid sequence encoded thereby is SEQ ID NO: 2, the light chain base sequence of the antibody is represented by SEQ ID NO: 3, The amino acid sequences encoded by are shown in SEQ ID NO: 4, respectively.
- the variable region of the heavy chain shown in SEQ ID NO: 2 consists of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 2, and the CDR1, CDR2, and CDR3 of the heavy chain are amino acid numbers 31 to 35 of SEQ ID NO: 2, respectively. It consists of an amino acid sequence from 50 to 65, 98 to 108.
- variable region of the light chain shown in SEQ ID NO: 4 consists of the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 4, and the CDR1, CDR2, and CDR3 of the light chain are amino acid numbers 24 to 38 of SEQ ID NO: 4, respectively. It consists of an amino acid sequence from 54 to 60, 93 to 101.
- the heavy chain base sequence of the prepared humanized antibody CL6_40m14_DDW is encoded by SEQ ID NO: 5, the amino acid sequence encoded thereby is SEQ ID NO: 6, and the light chain base sequence of the antibody is encoded by SEQ ID NO: 7.
- the amino acid sequence is shown in SEQ ID NO: 8, respectively.
- the variable region of the heavy chain shown in SEQ ID NO: 6 consists of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 6, and the CDR1, CDR2, and CDR3 of the heavy chain are amino acid numbers 31 to 35 of SEQ ID NO: 6, respectively. It consists of an amino acid sequence from 50 to 65, 98 to 108.
- variable region of the light chain shown in SEQ ID NO: 8 consists of the amino acid sequence from amino acid numbers 1 to 112 of SEQ ID NO: 8, and the CDR1, CDR2, and CDR3 of the light chain are amino acid numbers 24 to 38 of SEQ ID NO: 8, respectively. It consists of an amino acid sequence from 54 to 60, 93 to 101.
- the heavy chain base sequence of the prepared humanized antibody CL6_40m16_DDW is encoded by SEQ ID NO: 9, the amino acid sequence encoded thereby is SEQ ID NO: 10, and the light chain base sequence of the antibody is encoded by SEQ ID NO: 11.
- the amino acid sequence is shown in SEQ ID NO: 12, respectively.
- the variable region of the heavy chain shown in SEQ ID NO: 10 consists of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 10, and the CDR1, CDR2, and CDR3 of the heavy chain are amino acid numbers 31 to 35 of SEQ ID NO: 10, respectively. It consists of an amino acid sequence from 50 to 65, 98 to 108.
- variable region of the light chain shown in SEQ ID NO: 12 consists of the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 of the light chain are amino acid numbers 24 to 38 of SEQ ID NO: 12, respectively. It consists of an amino acid sequence from 54 to 60, 93 to 101.
- the CDR1, CDR2, and CDR3 of each heavy chain shown in SEQ ID NOs: 6 and 10 are the same as the CDR1, CDR2, CDR3 of the heavy chain shown in SEQ ID NO: 2, and each light chain shown in SEQ ID NOs: 8 and 12 CDR1, CDR2, and CDR3 are the same as the light chain CDR1, CDR2, and CDR3 shown in SEQ ID NO: 4.
- each humanized antibody In order to prepare each humanized antibody, the above-mentioned GS vector into which the heavy chain and light chain genes of each antibody were inserted was digested with NotI and PvuI and ligated using Ligation-Convenience Kit (NIPPONGENE). The Double-Gene vector in which both heavy chain and light chain genes were inserted was constructed.
- Expe293 cells Life Technologies
- Expofectamine 293 LifeTelge
- Exp293 cells (Life Technologies) grown to about 3 million cells / mL in Expi293 Expression Medium (Life Technologies). did.
- a purified antibody of each humanized antibody was obtained from the culture supernatant using protein G (GE Healthcare Japan).
- the antibody was expressed by transfecting the aforementioned Double-Gene vector into CHO-K1SV cells (Lonza Biologics). From the culture supernatant, purified antibodies of each humanized antibody were obtained using MabSelect SuRe (GE Healthcare Japan). As a result of analyzing the amino acid modification of each purified humanized antibody, in most of the purified antibodies, CL6_40m12_DDW showed a deletion of the lysine at the heavy chain C-terminal, and CL6_40m14_DDW showed pyroglutamine conversion and heavy chain C at the heavy chain N-terminal. In the case of CL6_40m16_DDW, the lysine deletion at the terminal occurred respectively in the heavy chain C-terminal.
- Example 4 ELISA assay for antigen
- Antigen ELISA was used to measure the antigen binding activity of the humanized antibody.
- the human Ig ⁇ -Flag protein obtained in Example 1 was prepared with Tris-buffered saline (TBS; Wako Pure Chemical Industries) so as to have a concentration of 5000 ng / mL, and Nunkumaxisorp white 384 plate (Maxisorp 384 plate). Nunc), 15 ⁇ L per well was added and solidified at room temperature for 1 hour.
- TBS Tris-buffered saline
- Nunkumaxisorp white 384 plate Maxisorp 384 plate
- an antigen ELISA assay using the monkey Ig ⁇ -Flag protein obtained in Example 1 was also performed.
- the measured value of the well not added with the test antibody was set to 0%, and the convergence value of the maximum activity of the test antibody was set to 100%.
- the calculated binding activity was analyzed, and the EC50 value of the test antibody was calculated by curve fitting.
- EC50 values of CL6_40m12_DDW for human and monkey Ig ⁇ -Flag proteins were 128 ng / mL and 183 ng / mL, respectively.
- EC50 values of CL6_40m14_DDW for human and monkey Ig ⁇ -Flag proteins were 100 ng / mL and 106 ng / mL, respectively.
- the EC50 values for human and monkey Ig ⁇ -Flag proteins of CL6_40m16_DDW were 132 ng / mL and 118 ng / mL, respectively.
- Each humanized antibody was confirmed to have high binding activity to both human and monkey Ig ⁇ -Flag proteins.
- Example 5 FACS analysis for human and monkey PBMC
- human and monkey PBMCs are used to target B cells contained in those PBMCs, and B20 marker CD20 as an index to Fluorescence Activated Cell sorting (FACS) analysis was performed.
- Monkey PBMC was prepared by diluting monkey blood with an equal volume of PBS (Life Technologies) and then stacking on an equal volume of Ficoll (GE Healthcare Japan) and centrifuging at room temperature, 1500 rpm for 30 minutes. .
- Human PBMC (AllCells) or monkey PBMC were seeded in a 96-well plate (Greiner) suspended in 30 ⁇ L of stain buffer (Becton, Dickinson) at 200,000 per well.
- Stain Buffer a dilution series of each humanized antibody obtained in Example 3 (four steps from a final concentration of 0.03 ⁇ g / mL to 30 ⁇ g / mL) was prepared, and 30 ⁇ L was added.
- each humanized antibody has high binding activity to both human and monkey B cells.
- Example 6 Evaluation of cell proliferation activity induced by anti-IgM antibody in human B cells
- anti-IgM antibody-induced cell proliferation activity in human B cells was evaluated.
- Anti-IgM antibodies cause B cell activation by aggregating BCR.
- An antibody that binds to both BCR and Fc ⁇ RIIb can recruit Fc ⁇ RIIb to the BCR, thereby inhibiting B cell proliferation.
- anti-CD19 S267E / L328F Patent Document 2 was used as a comparative antibody.
- a human IgG1 antibody (anti-KLH Ab) against KLH (keyhole limpet hemocyanin), which is an antigen not present in the living body, was used (International Publication No. 2013/094723).
- Human B cells (AllCells) were seeded in a 96-well plate (Iwaki) at about 30,000 per well in 60 ⁇ L of RPMI medium (SIGMA-ALDRICH).
- RPMI medium SIGMA-ALDRICH
- the results of the proliferation rate of human B cells are shown in FIG. Using the test antibody non-added / anti-IgM antibody non-added group as a negative control (growth rate 0%) and the test antibody non-added / anti-IgM antibody added group as a positive control (growth rate 100%), Calculated. The smaller the growth rate value, the stronger the inhibitory activity of the test antibody against BCR.
- the growth rate of anti-CD19 S267E / L328F at 30 ⁇ g / mL is 52.3%, while the growth rates of CL6_40m12_DDW, CL6_40m14_DDW and CL6_40m16_DDW at 30 ⁇ g / mL are 2. 8%, 20.2% and 23.2%. Therefore, it was revealed that all of the above-mentioned humanized antibodies have a strong inhibitory activity against anti-IgM antibody-induced cell proliferation in human B cells as compared to anti-CD19 S267E / L328F.
- Example 7 Evaluation of drug efficacy in human PBMC-introduced NOG mouse model
- Human PBMC Human PBMC (AllCells) was suspended in PBS (Wako Pure Chemical Industries) at 10 million cells / mL, and 0.25 mL (2.5 million cells) was added to 11-week-old male NOG mice (In vivo Science) in the tail vein. It was administered internally. Body weight measurement and blood sampling were performed on Day 34 (34 days after PBMC transfer). Plasma human IgM and IgE antibody titers were measured by ELISA (Bethyl Laboratories). Grouping was performed based on plasma human IgM, IgE antibody titer and body weight data.
- anti-CD19 S267E / L328F was used as a comparative antibody.
- Anti-KLH Ab was used as a control antibody.
- the test antibody was subcutaneously administered to mice at 10 mg / 10 mL / kg. Blood was collected on Day 42 and Day 49, and human IgM and IgE antibody titers in plasma were measured by ELISA (Bethyl Laboratories). Experiments were performed with 4-5 animals / group. The experimental results are shown as mean ⁇ standard error.
- the unsigned Student's t-test was used for the significant difference test between the anti-KLH Ab group and various test antibody groups, and was considered statistically significant when the p-value was less than 0.05. The above test was performed using GraphPad Prism (version 5.04).
- FIG. 2 shows the effect of the test antibody on the human IgM antibody titer in plasma.
- CL6_40m12_DDW and CL6_40m14_DDW significantly reduced plasma human IgM antibody titers.
- the onset of the decreasing effect of CL6_40m12_DDW and CL6_40m14_DDW on plasma human IgM antibody titer was very early and was observed from 1 week after the start of administration (Day 42).
- anti-CD19 S267E / L328F showed a significant lowering effect on the human IgM antibody titer in plasma only 2 weeks after the start of administration (Day 49).
- Example 8 Efficacy evaluation in monkey TTx antigen sensitization model
- Monkeys are sensitized once with precipitated tetanus toxoid (TTx) antigen to produce TTx antigen-specific IgG.
- TTx precipitated tetanus toxoid
- total antibody titer in plasma can also be evaluated. Therefore, this model can evaluate safety in addition to effectiveness in the treatment of autoimmune diseases.
- tetanus toxoid (TTx, 10 Lf / mL, Denka Seken Co., Ltd.) was injected into the thigh muscles at 0.6 mL / monkey and 0.6 mL / monkey into the dorsal skin (50 ⁇ L each at 12 locations). It was done by doing.
- the timing of administration was 14 days after TTx sensitization, and under awakening, the administration volume was 1 mL / kg from the vein.
- Precipitated tetanus toxoid (Denka Seiken Co., Ltd.) was diluted 20-fold with phosphate buffered saline (PBS; Wako Pure Chemical Industries), and 100 ⁇ L per well was added to Nunkumaxi soap 96 plate (Maxisorp 96 plate; Nunc). And solidified overnight at 4 ° C. After washing 4 times with PBS-T (PBS containing 0.05% Tween-20; Thermo Scientific), 200 ⁇ L of blocking agent (Blocker Casein in PBS; Life Technologies) was added and allowed to stand at room temperature for 2 hours. The solution was removed. Next, 100 ⁇ L of each of the collected plasma and calibration curve sample was added.
- PBS-T PBS containing 0.05% Tween-20; Thermo Scientific
- the standard curve sample was a mixture of plasma collected from cynomolgus monkeys immunized with precipitated tetanus toxoid 21 days and 23 days later, 100 U / mL, and a dilution series prepared using a blocking agent as a dilution solution (0.488 mU / mL to 500 mU / mL) was used. After standing at room temperature for 2 hours, the plate was washed 4 times with PBS-T washing solution, and 100 ⁇ L of horseradish peroxidase-labeled goat anti-monkey IgG antibody (Nordic) diluted 3000 times with a blocking agent was added.
- the plate was washed 4 times with a PBS-T washing solution. Then, it measured using TMB Microwell Peroxidase Substrate System (KPL company). Absorbance was measured with SpectraMax (Molecular Devices).
- FIG. 4 shows the effect of the test antibody on plasma anti-precipitation tetanus toxoid antibody titer.
- CL6_40m14_DDW decreased plasma anti-precipitation tetanus toxoid antibody titer (anti-TTx IgG) compared to the Vehicle group.
- the total antibody titer (IgM, IgA, IgG) in the plasma of Day 14, Day 17, Day 21, and Day 28 collected from the cynomolgus monkey was measured using the following method.
- Rabbit anti-monkey IgM polyclonal antibody (COVANCE) goat anti-human IgA polyclonal antibody (Bethyl Laboratories), goat anti-human IgG polyclonal antibody (Bethyl Laboratories), phosphate buffered saline (PBS; Wako Pure Chemical Industries) ), And diluted to 100 times, 500 times, and 1000 times, respectively, and 100 ⁇ L was added to a Nunkumaxisop 96 plate (Maxisorp 96 plate; Nunc) and solidified at 4 ° C.
- horseradish peroxidase-labeled anti-monkey IgM antibody KPL
- horseradish peroxidase-labeled anti-human IgA antibody Bethyl Laboratories
- Horseradish peroxidase-labeled anti-monkey IgG antibody KPL
- the plate was washed 4 times with a PBS-T washing solution. Then, it measured using TMB Microwell Peroxidase Substrate System (KPL company). Absorbance was measured with SpectraMax (Molecular Devices).
- the action of the test antibody on the total antibody titer (IgM, IgA, IgG) in plasma is shown in FIGS. 5, 6 and 7, respectively.
- CL6_40m14_DDW did not affect the total antibody titer (IgM, IgA, IgG) in plasma compared to the Vehicle group.
- the anti-human Ig ⁇ antibody of the present invention is useful for prevention or treatment of autoimmune diseases.
- the polynucleotide, expression vector, transformed host cell, and method for producing an antibody of the present invention are useful for producing the anti-human Ig ⁇ antibody.
- the base sequences shown in SEQ ID NOs: 5 and 7 are the heavy chain and light chain base sequences of CL6_40m14_DDW, respectively, and the amino acid sequences shown in SEQ ID NOs: 6 and 8 are respectively SEQ ID NOs: 5 and 7 Is the amino acid sequence of the heavy and light chains encoded by.
- the base sequences represented by SEQ ID NO: 9 and 11 in the sequence listing are the heavy chain and light chain base sequences of CL6_40m16_DDW, respectively.
- the amino acid sequences represented by SEQ ID NO: 10 and 12 in the sequence listing are respectively SEQ ID NO: 9 and 11 Is the amino acid sequence of the heavy and light chains encoded by.
- the base sequence shown in SEQ ID NO: 13 in the sequence listing is the base sequence of human Ig ⁇ -Flag gene, and the base sequence shown in SEQ ID NO: 14 in the sequence listing is the base sequence of monkey Ig ⁇ -Flag gene.
- the base sequence represented by SEQ ID NO: 15 in the Sequence Listing is the heavy chain base sequence of CL6_40m12_DDW.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(1)抗ヒトIgβ抗体であって、配列番号2のアミノ酸番号31から35までのアミノ酸配列からなるCDR1、配列番号2のアミノ酸番号50から65までのアミノ酸配列からなるCDR2、及び配列番号2のアミノ酸番号98から108までのアミノ酸配列からなるCDR3を含む重鎖可変領域、並びに配列番号4のアミノ酸番号24から38までのアミノ酸配列からなるCDR1、配列番号4のアミノ酸番号54から60までのアミノ酸配列からなるCDR2、及び配列番号4のアミノ酸番号93から101までのアミノ酸配列からなるCDR3を含む軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体。
(2)ヒト化抗体である、(1)に記載の抗ヒトIgβ抗体。
(3)以下の1)~4)からなる群より選択される、(1)に記載の抗ヒトIgβ抗体:
1)配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
2)配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
3)配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;並びに
4)上記1)~3)のいずれかの抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。
(4)配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、(3)に記載の抗ヒトIgβ抗体。
(5)配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、(3)に記載の抗ヒトIgβ抗体。
(6)配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、(3)に記載の抗ヒトIgβ抗体。
(7)(4)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。
(8)翻訳後修飾が、重鎖可変領域N末端のピログルタミル化及び/又は重鎖C末端のリジン欠失である、(3)又は(7)に記載の抗ヒトIgβ抗体。
(9)ヒトIgκ定常領域である軽鎖定常領域を含む、(1)~(8)のいずれか1項に記載の抗ヒトIgβ抗体。
(10)配列番号6に示されるアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、(1)に記載の抗ヒトIgβ抗体。
(11)配列番号2に示されるアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、(1)に記載の抗ヒトIgβ抗体。
(12)配列番号10に示されるアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、(1)に記載の抗ヒトIgβ抗体。
(13)(10)~(12)のいずれか1項に記載の抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。
(14)翻訳後修飾が、重鎖可変領域N末端のピログルタミル化及び/又は重鎖C末端のリジン欠失である、(13)に記載の抗ヒトIgβ抗体。
(15)アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、(13)に記載の抗ヒトIgβ抗体。
(16)配列番号2のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、(13)に記載の抗ヒトIgβ抗体。
(17)配列番号10のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、(13)に記載の抗ヒトIgβ抗体。
(18)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含む、ポリヌクレオチド。
(19)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含む、ポリヌクレオチド。
(20)(18)及び/又は(19)に記載のポリヌクレオチドを含む発現ベクター。
(21)以下の(a)~(d)からなる群より選択される、(20)に記載の発現ベクターで形質転換された宿主細胞:
(a)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
(c)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;及び
(d)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
(22)以下の(a)~(d)からなる群より選択される、(20)に記載の発現ベクターで形質転換された宿主細胞:
(a)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
(c)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;及び
(d)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
(23)以下の(a)~(c)からなる群より選択される宿主細胞を培養し、抗ヒトIgβ抗体を発現させる工程を包含する、抗ヒトIgβ抗体を生産する方法:
(a)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
(c)(1)~(6)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、及び、該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
(24)以下の(a)~(c)からなる群より選択される宿主細胞を培養し、抗ヒトIgβ抗体を発現させる工程を包含する、抗ヒトIgβ抗体を生産する方法:
(a)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
(c)(10)~(13)のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、及び、該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
(25)(23)に記載の方法で生産された抗ヒトIgβ抗体。
(26)(24)に記載の方法で生産された抗ヒトIgβ抗体。
(27)(1)~(17)、(25)及び(26)のいずれか1項に記載の抗ヒトIgβ抗体及び薬学的に許容される賦形剤を含む、医薬組成物。
(28)(10)に記載の抗ヒトIgβ抗体、(15)に記載の抗ヒトIgβ抗体及び薬学的に許容される賦形剤を含む、医薬組成物。
(29)自己免疫疾患の予防又は治療用の医薬組成物である、(27)又は(28)に記載の医薬組成物。
(30)自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病 である、(29)に記載の医薬組成物。
(31)(1)~(17)、(25)及び(26)のいずれか1項に記載の抗ヒトIgβ抗体の治療有効量を投与する工程を包含する、自己免疫疾患を予防又は治療する方法。
(32)自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、(31)に記載の方法。
(33)自己免疫疾患の予防又は治療に使用するための、(1)~(17)、(25)及び(26)のいずれか1項に記載の抗ヒトIgβ抗体。
(34)自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、(33)に記載の抗ヒトIgβ抗体。
(35)自己免疫疾患の予防又は治療用医薬組成物の製造における、(1)~(17)、(25)及び(26)のいずれか1項に記載の抗ヒトIgβ抗体に記載の抗ヒトIgβ抗体の使用。
(36)自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、(35)に記載の使用。
本発明の抗ヒトIgβ抗体には、以下の特徴を有する抗ヒトIgβ抗体が含まれる。
抗ヒトIgβ抗体であって、配列番号2のアミノ酸番号31から35までのアミノ酸配列からなるCDR1、配列番号2のアミノ酸番号50から65までのアミノ酸配列からなるCDR2、及び配列番号2のアミノ酸番号98から108までのアミノ酸配列からなるCDR3を含む重鎖可変領域、並びに配列番号4のアミノ酸番号24から38までのアミノ酸配列からなるCDR1、配列番号4のアミノ酸番号54から60までのアミノ酸配列からなるCDR2、及び配列番号4のアミノ酸番号93から101までのアミノ酸配列からなるCDR3を含む軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体。
1)配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
2)配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;並びに
3)配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体。
i)配列番号2に示されるアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体;
ii)配列番号6に示されるアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体;並びに
iii)配列番号10に示されるアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
1)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾され及び/又はアミノ酸番号449のリジンを欠く配列番号2のアミノ酸配列からなる重鎖、並びに配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
2)アミノ酸番号1のグルタミンがピログルタミン酸に修飾され及び/又はアミノ酸番号449のリジンを欠く配列番号6のアミノ酸配列からなる重鎖、並びに配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
3)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾され及び/又はアミノ酸番号449のリジンを欠く配列番号10のアミノ酸配列からなる重鎖、並びに配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
i)配列番号2のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
ii)アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体;並びに
iii)配列番号10のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
本発明のポリヌクレオチドには、本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチド、及び、本発明の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドが含まれる。
本発明の発現ベクターには、本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクター、本発明の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクター、及び本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターが含まれる。
本発明の形質転換された宿主細胞には、以下の(a)~(d)からなる群より選択される、本発明の発現ベクターで形質転換された宿主細胞が含まれる。
(a)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
(c)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;及び
(d)本発明の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
本発明の抗ヒトIgβ抗体を生産する方法には、以下の(a)~(c)からなる群より選択される宿主細胞を培養し、抗ヒトIgβ抗体を発現させる工程を包含する、抗ヒトIgβ抗体を生産する方法が含まれる。
(a)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
(c)本発明の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、及び、該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。
本発明の医薬組成物には、本発明の抗ヒトIgβ抗体及び薬学的に許容される賦形剤を含む医薬組成物が含まれる。本発明の医薬組成物は、当該分野において通常用いられている賦形剤、即ち、薬剤用賦形剤や薬剤用担体等を用いて、通常使用される方法によって調製することができる。これら医薬組成物の剤型の例としては、例えば、注射剤、点滴用剤等の非経口剤が挙げられ、静脈内投与、皮下投与等により投与することができる。製剤化にあたっては、薬学的に許容される範囲で、これら剤型に応じた賦形剤、担体、添加剤等を使用することができる。
(1)配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
(2)配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;並びに
(3)配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体。
(1)配列番号2のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(2)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾された配列番号2のアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(3)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾された配列番号2のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(4)配列番号2に示されるアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(1)配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(2)アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(3)アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(4)配列番号6に示されるアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(1)配列番号10のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(2)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾された配列番号10のアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(3)アミノ酸番号1のグルタミン酸がピログルタミン酸に修飾された配列番号10のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
(4)配列番号10に示されるアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、抗ヒトIgβ抗体。
配列番号6に示されるアミノ酸配列からなる重鎖及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む抗ヒトIgβ抗体、アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む抗ヒトIgβ抗体、並びに、薬学的に許容される賦形剤を含む、医薬組成物。
ヒトIgβにFlagタグを結合させた蛋白質(ヒトIgβ-Flag蛋白質)及びサルIgβにFlagタグを結合させた蛋白質(サルIgβ-Flag蛋白質)を取得した。ヒトIgβ-Flag遺伝子(配列番号13)をGSベクターpEE6.4(Lonza Biologics社)に組み換えた。サルIgβ-Flag遺伝子(配列番号14)をGSベクターpEE6.4(Lonza Biologics社)に組み換えた。作製した各ベクターを、FreeStyle MAX Reagent(Life Technologies社)を用いてFreeStyle 293細胞(Life Technologies社)へ遺伝子導入した。各細胞をFreeStyle 293 Expression medium(Life Technologies社)を用いた無血清培養系で1週間培養後、ヒトIgβ-Flag蛋白質又はサルIgβ-Flag蛋白質を含む培養上清をそれぞれ取得した。取得した培養上清から抗FLAG M2抗体アフィニティーゲル(SIGMA-ALDRICH社)を用いて蛋白質を精製し、以下の実験に使用した。
抗ヒトIgβ抗体を取得するため、C3H/HeJJmsSlc-lpr/lprマウス(日本エスエルシー)に、免疫反応を惹起するアジュバントと共に、実施例1で取得したヒトIgβ-Flag蛋白質及びサルIgβ-Flag蛋白質を免疫した。マウスを数回免疫し、最終免疫を行った。定法に従い、免疫したマウスの脾臓やリンパ節を摘出しリンパ球を収集し、これをマウスミエローマ細胞SP2/0(ATCC CRL-1581)と細胞融合することでハイブリドーマを作製した。ハイブリドーマの限界希釈サンプルを作製し、モノクローン化を行った。各クローンについて、拡大培養を行った後に無血清培地であるHybridoma SFM(Life Technologies社)に培地を変更し、3~5日間培養した。得られた培養上清から抗体精製キットProtein G Purification kit(Proteus社)を用いて抗体を精製した。
CL6_40の軽鎖及び重鎖のCDRを他のヒト抗体へ移植して、複数のヒト化抗体の重鎖及び軽鎖の遺伝子を作製した。GSベクター(Lonza Biologics社)を用いて、各ヒト化抗体の重鎖及び軽鎖の両遺伝子を含む発現ベクターを構築した。具体的には、各ヒト化抗体の重鎖可変領域遺伝子の5’側にシグナル配列(N.Whittleら,Protein Eng.,Vol.1,p.499-505,1987)をコードする遺伝子を、そして3’側にS239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1の定常領域遺伝子(配列番号1の塩基番号358から1350までの塩基配列からなる)をそれぞれ繋げ、この重鎖遺伝子をGSベクターpEE6.4に挿入した。また、これらの各ヒト化抗体の軽鎖可変領域遺伝子の5’側にシグナル配列(N.Whittleら、前出)をコードする遺伝子を、そして3’側にヒトκ鎖の定常領域遺伝子(配列番号3の塩基番号337から657までの塩基配列からなる)をそれぞれ繋げ、この軽鎖遺伝子をGSベクターpEE12.4に挿入した。
ヒト化抗体の抗原結合活性を測定するために、抗原ELISAを使用した。実施例1で取得したヒトIgβ-Flag蛋白質を、5000ng/mLの濃度になるようにトリス緩衝生理食塩水(TBS;Wako Pure Chemical Industries社)で調製し、ヌンクマキシソープ白色384プレート(Maxisorp 384 plate;Nunc社)に1ウェルあたり15μL添加して室温で1時間固相化した。TBS-T(0.05% Tween-20含有TBS;Wako Pure Chemical Industries社)で2回洗浄後、ブロッキング剤(Blocking One;nacalai tesque社)を120μL添加し、室温にて1時間静置した後、その溶液を除去した。ブロッキング剤とTBSを等量ずつ加えた希釈溶液を使って、実施例3で取得した各ヒト化抗体の希釈系列(最終濃度が0.46ng/mLから1μg/mLの8段階)を作製し、15μL添加した。室温にて1時間静置した後、TBS-T洗浄液にて3回洗浄し、希釈溶液で3000倍に希釈したホースラディッシュぺルオキシダーゼ標識ラビット抗ヒトIg抗体(DAKO社)を20μL添加した。室温にて1時間静置した後、TBS-T洗浄液で3回洗浄した。化学発光検出試薬であるBM-Chemiluminescence ELISA Substrate(POD)(Roche Diagnostics社)を30μL加えて、その化学発光量をEnVisionカウンター(PerkinElmer社)で測定した。同様の方法で、実施例1で取得したサルIgβ-Flag蛋白質を用いた抗原ELISAアッセイも実施した。被験抗体の各濃度における結合活性を算出するにあたり、被験抗体非添加のウェルの測定値を0%とし、被験抗体の最大活性の収束値を100%と設定した。算出された結合活性を解析し、曲線当てはめにより被験抗体のEC50値を算出した。
ヒト及びサルB細胞に対するヒト化抗体の結合活性を評価するために、ヒト及びサルPBMCを用いて、それらのPBMC中に含まれるB細胞を対象として、B細胞マーカーであるCD20を指標にFluorescence Activated Cell Sorting(FACS)解析を行った。サルPBMCは、サル血液を等量のPBS(Life Technologies社)にて希釈後、等量のFicoll(GE Healthcare Japan社)の上に積層し、室温、1500rpm、30分間遠心処理することによって調製した。ヒトPBMC(AllCells社)又はサルPBMCを、96ウェルプレート(Greiner社)に1ウェルあたり20万個で、30μLのStain Buffer(Becton,Dickinson社)に懸濁して播種した。Stain Bufferを使って、実施例3で取得した各ヒト化抗体の希釈系列(最終濃度が0.03μg/mLから30μg/mLの4段階)を作製し、30μL添加した。氷上で30分間静置した後、Stain Bufferにて3回洗浄し、Stain Bufferで200倍希釈したフィコエリトリン標識ヤギ抗ヒトIgG Fcγフラグメント(JACKSON社)と8倍希釈したアロフィコシアニン標識マウス抗CD20抗体(Becton,Dickinson社)を含む溶液を40μL添加した。氷上で30分間静置した後、Stain Bufferにて2回洗浄後、FACSArray(Becton,Dickinson社)にて蛍光強度を測定し、平均蛍光強度(mean fluorescence intensity;MFI)を算出した。解析にはFlowJo(TOMY DIGITAL BIOLOGY社)を使用した。
BCR刺激によるヒトB細胞の活性化に対するヒト化抗体の阻害効果を評価するために、ヒトB細胞における抗IgM抗体誘発細胞増殖活性を評価した。抗IgM抗体は、BCRを凝集させることで、B細胞の活性化をもたらす。BCR及びFcγRIIbの双方に結合する抗体は、BCRにFcγRIIbを動員し、それによってB細胞の増殖を阻害することができる。本実施例では、比較抗体として、anti-CD19 S267E/L328F(特許文献2)を用いた。コントロール抗体として、生体内に存在しない抗原であるKLH(keyhole limpet hemocyanin)に対するヒトIgG1抗体(anti-KLH Ab)を用いた(国際公開第2013/094723号)。ヒトB細胞(AllCells社)を、96ウェルプレート(Iwaki社)に1ウェルあたり約3万個で、60μLのRPMI培地(SIGMA-ALDRICH社)で播種した。RPMI培地を使って、実施例3で取得した各ヒト化抗体、anti-CD19 S267E/L328F、又はanti-KLH Abの希釈系列(最終濃度が0.3μg/mLから30μg/mLの3段階)を作製し20μL添加した。RPMI培地で最終濃度が5μg/mLになるように調製した抗IgM抗体(JACKSON社)を20μL添加し、4日間CO2インキュベータにてインキュベートした。その後、CellTiter-Glo(Promega社)を用いて、細胞増殖解析を行った。また、本実施例において、陰性対照として被験抗体非添加/抗IgM抗体非添加群、陽性対照として被験抗体非添加/抗IgM抗体添加群を調製して試験した。各被験抗体について、デュプリケートで試験を行った。
ヒト化抗体のin vivo抗体産生に対する有効性を確認する目的として、ヒトPBMCをNOGマウスに移入することによって惹起されるヒト抗体価の上昇に対する各種抗体の治療投与における作用を評価した。本モデルでは、異物(マウス)認識により激しく活性化されたヒトB細胞が、マウス体内でプラズマ(ブラスト)細胞まで分化すると考えられ、ヒトB系列細胞の活性化に対する被験薬の薬理作用を評価するには適したモデルであると考えられる。
サルに沈降破傷風トキソイド(TTx)抗原を1回感作させることによりTTx抗原特異的なIgGが産生される。本モデルでは、血漿中のTTx抗原特異的IgGに加えて、血漿中の総抗体価も評価ができる。したがって、本モデルは、自己免疫疾患の治療にあたり、有効性に加えて、安全性の評価も可能となる。
表1:サルにおけるヒト化抗Igβ抗体の血漿中薬物濃度推移
Claims (36)
- 抗ヒトIgβ抗体であって、配列番号2のアミノ酸番号31から35までのアミノ酸配列からなるCDR1、配列番号2のアミノ酸番号50から65までのアミノ酸配列からなるCDR2、及び配列番号2のアミノ酸番号98から108までのアミノ酸配列からなるCDR3を含む重鎖可変領域、並びに配列番号4のアミノ酸番号24から38までのアミノ酸配列からなるCDR1、配列番号4のアミノ酸番号54から60までのアミノ酸配列からなるCDR2、及び配列番号4のアミノ酸番号93から101までのアミノ酸配列からなるCDR3を含む軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体。
- ヒト化抗体である、請求項1に記載の抗ヒトIgβ抗体。
- 以下の(1)~(4)からなる群より選択される、請求項1に記載の抗ヒトIgβ抗体:
(1)配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
(2)配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;
(3)配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、抗ヒトIgβ抗体;並びに
(4)上記(1)~(3)のいずれかの抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。 - 配列番号6のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号8のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、請求項3に記載の抗ヒトIgβ抗体。
- 配列番号2のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号4のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、請求項3に記載の抗ヒトIgβ抗体。
- 配列番号10のアミノ酸番号1から119までのアミノ酸配列からなる重鎖可変領域、及び配列番号12のアミノ酸番号1から112までのアミノ酸配列からなる軽鎖可変領域を含み、S239D、H268D、及びL328Wのアミノ酸変異を有するヒトIgγ1定常領域である重鎖定常領域を含む、請求項3に記載の抗ヒトIgβ抗体。
- 請求項4~6のいずれか1項に記載の抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。
- 翻訳後修飾が、重鎖可変領域N末端のピログルタミル化及び/又は重鎖C末端のリジン欠失である、請求項3又は7に記載の抗ヒトIgβ抗体。
- ヒトIgκ定常領域である軽鎖定常領域を含む、請求項1~8のいずれか1項に記載の抗ヒトIgβ抗体。
- 配列番号6に示されるアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、請求項1に記載の抗ヒトIgβ抗体。
- 配列番号2に示されるアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、請求項1に記載の抗ヒトIgβ抗体。
- 配列番号10に示されるアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、請求項1に記載の抗ヒトIgβ抗体。
- 請求項10~12のいずれか1項に記載の抗ヒトIgβ抗体の翻訳後修飾により生じた抗ヒトIgβ抗体。
- 翻訳後修飾が、重鎖可変領域N末端のピログルタミル化及び/又は重鎖C末端のリジン欠失である、請求項13に記載の抗ヒトIgβ抗体。
- アミノ酸番号1のグルタミンがピログルタミン酸に修飾された配列番号6のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号8に示されるアミノ酸配列からなる軽鎖を含む、請求項13に記載の抗ヒトIgβ抗体。
- 配列番号2のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号4に示されるアミノ酸配列からなる軽鎖を含む、請求項13に記載の抗ヒトIgβ抗体。
- 配列番号10のアミノ酸番号1から448までのアミノ酸配列からなる重鎖、及び配列番号12に示されるアミノ酸配列からなる軽鎖を含む、請求項13に記載の抗ヒトIgβ抗体。
- 請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含む、ポリヌクレオチド。
- 請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含む、ポリヌクレオチド。
- 請求項18及び/又は19に記載のポリヌクレオチドを含む発現ベクター。
- 以下の(a)~(d)からなる群より選択される、請求項20に記載の発現ベクターで形質転換された宿主細胞:
(a)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
(c)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;及び
(d)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。 - 以下の(a)~(d)からなる群より選択される、請求項20に記載の発現ベクターで形質転換された宿主細胞:
(a)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
(c)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;及び
(d)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。 - 以下の(a)~(c)からなる群より選択される宿主細胞を培養し、抗ヒトIgβ抗体を発現させる工程を包含する、抗ヒトIgβ抗体を生産する方法:
(a)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
(c)請求項1~6のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、及び、該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。 - 以下の(a)~(c)からなる群より選択される宿主細胞を培養し、抗ヒトIgβ抗体を発現させる工程を包含する、抗ヒトIgβ抗体を生産する方法:
(a)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドとを含む発現ベクターで形質転換された宿主細胞;
(b)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
(c)請求項10~13のいずれか1項に記載の抗ヒトIgβ抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、及び、該抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞。 - 請求項23に記載の方法で生産された抗ヒトIgβ抗体。
- 請求項24に記載の方法で生産された抗ヒトIgβ抗体。
- 請求項1~17、25及び26のいずれか1項に記載の抗ヒトIgβ抗体及び薬学的に許容される賦形剤を含む、医薬組成物。
- 請求項10に記載の抗ヒトIgβ抗体、請求項15に記載の抗ヒトIgβ抗体及び薬学的に許容される賦形剤を含む、医薬組成物。
- 自己免疫疾患の予防又は治療用の医薬組成物である、請求項27又は28に記載の医薬組成物。
- 自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、請求項29に記載の医薬組成物。
- 請求項1~17、25及び26のいずれか1項に記載の抗ヒトIgβ抗体の治療有効量を投与する工程を包含する、自己免疫疾患を予防又は治療する方法。
- 自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、請求項31に記載の方法。
- 自己免疫疾患の予防又は治療に使用するための、請求項1~17、25及び26のいずれか1項に記載の抗ヒトIgβ抗体。
- 自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、請求項33に記載の抗ヒトIgβ抗体。
- 自己免疫疾患の予防又は治療用医薬組成物の製造における、請求項1~17、25及び26のいずれか1項に記載の抗ヒトIgβ抗体に記載の抗ヒトIgβ抗体の使用。
- 自己免疫疾患が、全身性エリテマトーデス、関節リウマチ又は特発性血小板減少性紫斑病である、請求項35に記載の使用。
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580042306.6A CN106574259B (zh) | 2014-08-06 | 2015-08-05 | 新的抗人类Igβ抗体 |
SG11201700885SA SG11201700885SA (en) | 2014-08-06 | 2015-08-05 | NOVEL ANTI-HUMAN Igβ ANTIBODY |
PL15829154T PL3178929T3 (pl) | 2014-08-06 | 2015-08-05 | Nowe przeciwciało przeciwko ludzkiej ig(beta) |
AU2015300080A AU2015300080B2 (en) | 2014-08-06 | 2015-08-05 | New anti-human Igbeta antibody |
JP2016540256A JP6627761B2 (ja) | 2014-08-06 | 2015-08-05 | 新規抗ヒトIgβ抗体 |
MYPI2017700380A MY181914A (en) | 2014-08-06 | 2015-08-05 | Novel anti-human ig? antibody |
UAA201702067A UA121866C2 (uk) | 2014-08-06 | 2015-08-05 | АНТИТІЛО ДО Ig<font face="Symbol">b </font>ЛЮДИНИ |
BR112017002237A BR112017002237A2 (pt) | 2014-08-06 | 2015-08-05 | novo anticorpo anti-igss humana |
KR1020177003135A KR102488214B1 (ko) | 2014-08-06 | 2015-08-05 | 신규 항-인간 Igβ 항체 |
EP15829154.2A EP3178929B1 (en) | 2014-08-06 | 2015-08-05 | New anti-human ig(beta) antibody |
RU2017106743A RU2710532C2 (ru) | 2014-08-06 | 2015-08-05 | НОВОЕ АНТИТЕЛО ПРОТИВ Igβ ЧЕЛОВЕКА |
CA2957313A CA2957313C (en) | 2014-08-06 | 2015-08-05 | Novel anti-human ig.beta. antibody |
IL250404A IL250404B (en) | 2014-08-06 | 2015-08-05 | A new anti-igbeta antibody of human origin |
US15/501,626 US10316086B2 (en) | 2014-08-06 | 2015-08-05 | Anti-human Igβ antibody |
ES15829154T ES2886443T3 (es) | 2014-08-06 | 2015-08-05 | Nuevo anticuerpo anti-Ig(beta) humana |
MX2017001642A MX2017001642A (es) | 2014-08-06 | 2015-08-05 | ANTICUERPO IGß ANTIHUMANO NOVEDOSO. |
PH12017500201A PH12017500201A1 (en) | 2014-08-06 | 2017-02-02 | NOVEL ANTI-HUMAN Ig� ANTIBODY |
US16/392,418 US11059889B2 (en) | 2014-08-06 | 2019-04-23 | Anti-human Igβ antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014160141 | 2014-08-06 | ||
JP2014-160141 | 2014-08-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/501,626 A-371-Of-International US10316086B2 (en) | 2014-08-06 | 2015-08-05 | Anti-human Igβ antibody |
US16/392,418 Continuation US11059889B2 (en) | 2014-08-06 | 2019-04-23 | Anti-human Igβ antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016021621A1 true WO2016021621A1 (ja) | 2016-02-11 |
Family
ID=55263882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/072162 WO2016021621A1 (ja) | 2014-08-06 | 2015-08-05 | 新規抗ヒトIgβ抗体 |
Country Status (22)
Country | Link |
---|---|
US (2) | US10316086B2 (ja) |
EP (1) | EP3178929B1 (ja) |
JP (1) | JP6627761B2 (ja) |
KR (1) | KR102488214B1 (ja) |
CN (1) | CN106574259B (ja) |
AR (1) | AR102042A1 (ja) |
AU (1) | AU2015300080B2 (ja) |
BR (1) | BR112017002237A2 (ja) |
CA (1) | CA2957313C (ja) |
ES (1) | ES2886443T3 (ja) |
IL (1) | IL250404B (ja) |
MA (1) | MA40321A (ja) |
MX (1) | MX2017001642A (ja) |
MY (1) | MY181914A (ja) |
PH (1) | PH12017500201A1 (ja) |
PL (1) | PL3178929T3 (ja) |
PT (1) | PT3178929T (ja) |
RU (1) | RU2710532C2 (ja) |
SG (1) | SG11201700885SA (ja) |
TW (1) | TWI681971B (ja) |
UA (1) | UA121866C2 (ja) |
WO (1) | WO2016021621A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020156439A1 (zh) | 2019-01-28 | 2020-08-06 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008150494A1 (en) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
JP2013540696A (ja) * | 2010-08-02 | 2013-11-07 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101254302B (zh) * | 1999-05-07 | 2011-05-11 | 杰南技术公司 | 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病 |
US20020150573A1 (en) * | 2000-11-10 | 2002-10-17 | The Rockefeller University | Anti-Igalpha-Igbeta antibody for lymphoma therapy |
CA2461529A1 (en) * | 2001-09-25 | 2003-04-03 | Immuno-Biological Laboratories Co., Ltd. | Recombinant anti-osteopontin antibody and use thereof |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
AU2006252406B2 (en) * | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
CA2624081C (en) * | 2005-09-29 | 2014-09-16 | Medimmune, Inc. | Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
PL2064325T3 (pl) * | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek |
PT2176296E (pt) | 2007-07-16 | 2012-05-14 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
MY157403A (en) * | 2008-01-31 | 2016-06-15 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
-
2015
- 2015-08-05 AU AU2015300080A patent/AU2015300080B2/en active Active
- 2015-08-05 PL PL15829154T patent/PL3178929T3/pl unknown
- 2015-08-05 CN CN201580042306.6A patent/CN106574259B/zh active Active
- 2015-08-05 US US15/501,626 patent/US10316086B2/en active Active
- 2015-08-05 WO PCT/JP2015/072162 patent/WO2016021621A1/ja active Application Filing
- 2015-08-05 ES ES15829154T patent/ES2886443T3/es active Active
- 2015-08-05 TW TW104125426A patent/TWI681971B/zh active
- 2015-08-05 KR KR1020177003135A patent/KR102488214B1/ko active IP Right Grant
- 2015-08-05 BR BR112017002237A patent/BR112017002237A2/pt active Search and Examination
- 2015-08-05 MA MA040321A patent/MA40321A/fr unknown
- 2015-08-05 MY MYPI2017700380A patent/MY181914A/en unknown
- 2015-08-05 IL IL250404A patent/IL250404B/en unknown
- 2015-08-05 CA CA2957313A patent/CA2957313C/en active Active
- 2015-08-05 EP EP15829154.2A patent/EP3178929B1/en active Active
- 2015-08-05 MX MX2017001642A patent/MX2017001642A/es unknown
- 2015-08-05 PT PT158291542T patent/PT3178929T/pt unknown
- 2015-08-05 SG SG11201700885SA patent/SG11201700885SA/en unknown
- 2015-08-05 UA UAA201702067A patent/UA121866C2/uk unknown
- 2015-08-05 RU RU2017106743A patent/RU2710532C2/ru active
- 2015-08-05 AR ARP150102510A patent/AR102042A1/es unknown
- 2015-08-05 JP JP2016540256A patent/JP6627761B2/ja active Active
-
2017
- 2017-02-02 PH PH12017500201A patent/PH12017500201A1/en unknown
-
2019
- 2019-04-23 US US16/392,418 patent/US11059889B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008150494A1 (en) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
JP2013540696A (ja) * | 2010-08-02 | 2013-11-07 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
Non-Patent Citations (3)
Title |
---|
NAKAMURA T. ET AL.: "Signal transduction in human B cells initiated via Ig beta ligation.", INT IMMUNOL., vol. 5, no. 10, 1993, pages 1309 - 1315, XP008042539 * |
NAKAMURA T. ET AL.: "Suppression of humoral immunity by monoclonal antibody to CD 79b, an invariant component of antigen receptors on B lymphocytes.", INT J HEMATOL., vol. 64, no. 1, 1996, pages 39 - 46, XP008042560, DOI: doi:10.1016/0925-5710(96)00464-1 * |
See also references of EP3178929A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020156439A1 (zh) | 2019-01-28 | 2020-08-06 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11059889B2 (en) | Anti-human Igβ antibody | |
US9908941B2 (en) | Anti-human TSLP receptor antibody | |
CN116693686A (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
JP6604204B2 (ja) | 新規抗ヒトbdca−2抗体 | |
CN106062193B (zh) | 与人tlr2及人tlr4结合的双特异性抗体 | |
US20230242646A1 (en) | Humanized Anti-Human CD89 Antibodies and Uses Thereof | |
JP6529602B2 (ja) | 抗cd20/抗baff二重特異性抗体 | |
TW202144425A (zh) | 特異性抗原結合分子,其製備方法及醫藥用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15829154 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016540256 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 250404 Country of ref document: IL Ref document number: 12017500201 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 20177003135 Country of ref document: KR Kind code of ref document: A Ref document number: 2957313 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015829154 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/001642 Country of ref document: MX Ref document number: 2015829154 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017002237 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015300080 Country of ref document: AU Date of ref document: 20150805 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017106743 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201702067 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 112017002237 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170202 |